Apple and Masimo's patent and trade secret dispute has intensified through lawsuits as Apple defends its innovations and ...

Masimo delivered Q3 results that mostly aligned with guidance, yet it faces challenges in its non-healthcare segment.

User-friendly touch-screen patient monitor measures ECG, SpO 2, NIBP, heart rate, temperature and respiration. Offers optional dual IBP, and EtCo 2 — Now with Masimo SET ® Pulse Oximetry!

Smartwatches gather vast amounts of data about our physiology. Now their technology is being harnessed like never before.

Needham analyst Michael Matson maintained a Hold rating on Masimo (MASI – Research Report) today. The company’s shares closed ...

Vanderbilt University Medical Center is launching Masimo Radius VSM™ advanced wireless patient-worn vital signs monitoring ...

In a report released today, Marie Thibault from BTIG maintained a Buy rating on Masimo (MASI – Research Report), with a price target of ...

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. TipRanks is the most comprehensive data set of sell side ...

A federal jury ruled Friday that Masimo smartwatches infringed Apple patents, but Apple isn’t getting a big payday. Bloomberg Law reports that the company was only seeking the statutory minimum ...

Masimo (NASDAQ:MASI) is set to give its latest quarterly earnings report on Tuesday, 2024-11-05. Here's what investors need to know before the announcement. Analysts estimate that Masimo will ...

Ladies and gentlemen, good afternoon, and welcome to Masimo's Third Quarter 2024 Earnings ... continue to benefit from the relocation of our sensor manufacturing to Malaysia in combination with ...